⚡ Core Concept: Dysregulated Cell Cycle Control & Oncogenic Transformation
Malignant neoplastic transformation arises from accumulated genetic and epigenetic lesions that disrupt cell cycle checkpoints. Hallmarks include loss of tumor suppressor brakes ($TP53, RB1, CDKN2A$), constitutive hyperactivation of proto-oncogenic signaling ($KRAS, MYC, CCND1$), and evasion of contact inhibition and apoptotic death.
1. The Two Guardian Pathways: p53 and pRb
Virtually all human cancers compromise either the p53 apoptotic surveillance axis or the pRb $G_1/S$ checkpoint gatekeeper:
Figure 3: Molecular Signaling Architecture of the p53 and pRb Tumor Suppressor Networks
Oncology & Pathobiology
Figure 3: Interplay between genotoxic stress response mediated by p53 (inducing p21-mediated arrest or Bax/Puma-mediated apoptosis) and mitogenic restriction release via pRb hyperphosphorylation.
2. Oncogenes vs. Tumor Suppressor Genes: Genetics & Mechanisms
| Feature | Proto-Oncogenes (e.g., RAS, MYC, HER2) | Tumor Suppressors (e.g., TP53, RB1, PTEN, APC) |
|---|---|---|
| Mutational Nature | Gain-of-Function (dominant; single allele sufficient) | Loss-of-Function (recessive; Knudson’s “two-hit” hypothesis) |
| Mechanism | Point mutations, amplifications, chromosomal translocations | Nonsense mutations, deletions, epigenetic promoter hypermethylation |
| Normal Role | Stimulate cell growth, proliferation, survival | Enforce cell cycle checkpoints, repair DNA, promote apoptosis |
| Classical Example | BCR-ABL fusion in CML; KRAS G12D in pancreatic cancer | RB1 in Retinoblastoma; TP53 in Li-Fraumeni Syndrome |
3. Targeted Therapeutic Strategies in Cell Cycle Oncology
Modern precision oncology directly exploits cell cycle vulnerabilities:
- CDK4/6 Inhibitors (Palbociclib, Ribociclib): Selectively block Cyclin D-CDK4/6 kinase activity, maintaining pRb in its unphosphorylated tumor-suppressive state to arrest HR+/HER2- breast cancer cells in $G_1$.
- PARP Inhibitors (Olaparib): Exploit synthetic lethality in BRCA1/2-deficient tumors. Inactivating PARP-mediated single-strand break repair forces replication fork collapse into double-strand breaks, which HR-deficient cancer cells cannot repair.
- WEE1 Inhibitors (Adavosertib): Force p53-deficient tumor cells with DNA damage past the $G_2/M$ checkpoint, triggering mitotic catastrophe.
Knudson’s Two-Hit Model & Loss of Heterozygosity (LOH)
Alfred Knudson’s retinoblastoma study established that familial cancer syndromes inherit one inactivated germline tumor suppressor allele (“first hit”). Tumorigenesis requires somatic inactivation of the second wild-type allele (“second hit”) through deletion, mitotic recombination, or epigenetic promoter methylation—a hallmark termed Loss of Heterozygosity.
